share_log
Benzinga ·  May 10 08:04
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment